rmdopen.bmj2d
From patients with arthralgia, pre-RA and recently diagnosed RA: what is the current status of understanding RA pathogenesis?
It is believed that therapy for rheumatoid arthritis (RA) is the most effective and beneficial within a short time frame around RA diagnosis. This insight has caused a shift from research in patients ...
rmdopen.bmj18d
Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells
Objectives Interleukin (IL)-17 signalling has been shown to be a key regulator of disease in ankylosing spondylitis (AS) with several IL-17 blockers currently clinically approved. Despite this, the ...
rmdopen.bmj19d
CAR T cells for treating autoimmune diseases
Autoimmune disorders occur when immune cells go wrong and attack the body’s own tissues. Currently, autoimmune disorders are largely treated by broad immunosuppressive agents and blocking antibodies, ...
rmdopen.bmj19d
Association between diabetes mellitus and osteoarthritis: systematic literature review and meta-analysis
Objectives To investigate the prevalence of osteoarthritis (OA) in patients with diabetes mellitus (DM) and prevalence of DM in patients with OA and whether OA and DM are associated. Design A ...
rmdopen.bmj19d
Lymph nodes as gatekeepers of autoimmune diseases
3 Amsterdam Institute for Immunology and Infectious diseases, Amsterdam, The Netherlands 4 Amsterdam Rheumatology and Immunology Centre (ARC), Amsterdam, The Netherlands Secondary lymphoid organs such ...
rmdopen.bmj19d
Metabolomic profiles, polygenic risk scores and risk of rheumatoid arthritis: a population-based cohort study in the UK Biobank
Objective To investigate the relationship between metabolomic profiles, genome-wide polygenic risk scores (PRSs) and risk of rheumatoid arthritis (RA). Methods 143 nuclear magnetic resonance-based ...
rmdopen.bmj1mon
Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease
3 Interdepartmental Research Center of Systemic Autoimmune and Autoinflammatory Diseases, Rheumatology Unit, Policlinico Le Scotte, University of Siena, Siena, Italy Blau syndrome (BS) and early-onset ...
rmdopen.bmj1mon
Low apolipoprotein A1 and high apolipoprotein B levels indicate specific lipid changes in treatment naïve early psoriatic arthritis
Objectives To investigate serum lipid profile in early, treatment-naïve psoriatic arthritis (PsA) and to determine whether changes in classical lipids or apolipoproteins are specific to PsA. Methods ...
rmdopen.bmj1mon
Mixed connective tissue disease: state of the art on clinical practice guidelines
Mixed connective tissue disease (MCTD) is a complex overlap disease with features of different autoimmune connective tissue diseases (CTDs) namely systemic sclerosis, poly/dermatomyositis and systemic ...
rmdopen.bmj1mon
Use of artificial intelligence in imaging in rheumatology – current status and future perspectives
After decades of basic research with many setbacks, artificial intelligence (AI) has recently obtained significant breakthroughs, enabling computer programs to outperform human interpretation of ...
rmdopen.bmj1mon
Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study
Objective Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for treating gout and asymptomatic hyperuricaemia. This study evaluated the pharmacodynamics, ...
rmdopen.bmj1mon
Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
Objective To evaluate the magnitude of response to secukinumab treatment over 3 years in patients with ankylosing spondylitis (AS) grouped by baseline C-reactive protein (CRP) levels in a pooled study ...